Nycomed, ALVESCO , FDA approval for the U.S. market

15.01.2008 - Nycomed announced today that the Food and Drug Administration (FDA) approved ALVESCO (ciclesonide) Inhalation Aerosol in the United States for the maintenance treatment of asthma and as prophylactic therapy in adult and adolescent patients aged 12 years and older. ALVESCO is an inhaled corticosteroid with novel release and distribution properties...
...ALVESCO is based on the active ingredient ciclesonide which is Nycomed’s patented corticosteroid with a novel principle of action. Ciclesonide is a prodrug that is activated by intracellular esterases following oral inhalation. ALVESCO has wide inhibitory activities against multiple inflammatory cell types and chemicals involved in the asthmatic response... Nycomed's Press Release-